A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma-Reference-Cited by-同舟云学术

A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Published:2021-01-28 Issue:7 Volume:62 Page:1721-1729
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Khan Sahar¹,LeBlanc Richard²,Gyger Martin³,White Darrell⁴,Kaufman Johnathan⁵,Jazubowiak Andrzej⁶,Gul Engin¹,Paul Harminder¹,Le Lisa W.⁷,Lau Anthea⁷,Li Zhihua¹,Trudel Suzanne⁸

Affiliation:

1. Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada

2. Hȏspital Maisonneuve-Rosemont, Montreal, Canada

3. Jewish General Hospital, Montreal, Canada

4. Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Canada

5. Winship Cancer Institute Emory University School of Medicine, Atlanta, GA, USA

6. Division of Hematology/Oncology, University of Chicago Medical Center, Chicago, IL, USA

7. Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, Canada

8. Princess Margaret Cancer Centre Ontario Cancer Institute, Toronto, Canada

Funder

Astellas

Multiple Myeloma Research Consortium

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1876864

Reference35 articles.

1. NIH, Surveillance, Epidemiology, and End Results Program [Internet]. Cancer Stat Facts: Myeloma, 2010-2016. Available at: https://seer.cancer.gov/statfacts/html/mulmy.html.

2. Nandakumar B, Binder M, Dispenzieri A, et al. Continued improvement in survival in multiple myeloma (MM) including high-risk patients. Presented at: American Society of Clinical Oncology Annual Meeting; May 31–June 4 2019. Chicago, Illinois. Suppl Abstract 8039

3. Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome

4. Insulin-like growth factors and neoplasia

5. Insulin-Like Growth Factor Receptor-1 as an Anti-Cancer Target: Blocking Transformation and Inducing Apoptosis

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial;Nature Communications;2024-08-11

2. In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants;European Journal of Pharmaceutical Sciences;2024-08

3. Recent Advances of Second‐Line Targeted Biopharmaceutical Therapies in Thyroid Associated Ophthalmopathy;Advanced Therapeutics;2024-07-05

4. Functional Investigation of IGF1R Mutations in Multiple Myeloma;Cancers;2024-06-04

5. Extracellular Interactors of the IGF System: Impact on Cancer Hallmarks and Therapeutic Approaches;International Journal of Molecular Sciences;2024-05-29